New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 18, 2014
14:55 EDTAZN, PFEPfizer said to be preparing improved offer for AstraZeneca, WSJ says
Pfizer (PFE) is said to be preparing an improved take-over offer for AstraZeneca (AZN) on Sunday in the hopes of enticing AstraZeneca back to the negotiating table, says the Wall Street Journal. According to people familiar with the matter, Pfizer may 'walk away' from the proposed deal if this latest attempt is turned down, added the Wall Street Journal. Reference Link
News For PFE;AZN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
June 24, 2015
13:23 EDTPFEPfizer says CDC committee votes to recommend MenB vaccine
Pfizer announced that the U.S. Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices voted to recommend that decisions to vaccinate adolescents and young adults 16 through 23 years of age against serogroup B meningococcal disease should be made at the individual level with healthcare providers. It added, "Specifically, the ACIP voted that a serogroup B meningococcal vaccine series may be administered to adolescents and young adults 16 through 23 years of age to provide short term protection against most strains of serogroup B meningococcal disease. The preferred age for MenB vaccination is 16 through 18 years of age." Pfizer's Trumenba is FDA-approved for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B in individuals 10 through 25 years of age. The ACIP recommendation will be forwarded to the director of the CDC and the U.S. Department of Health and Human Services for review and approval, Pfizer said.
11:02 EDTPFEPfizer lung cancer treatment granted FDA orphan drug designation
Subscribe for More Information
09:07 EDTPFE, AZNCAR-T cancer drug researchers seen as M&A targets, Bloomberg says
Juno Therapeutics (JUNO), Kite Pharma (KITE) and Bluebird Bio (BLUE) are trading well above their IPO levels as takeovers predictions have spurred interest and share increases for the developers of CAR-T gene therapies, said Bloomberg's "Real M&A" column, quoting Dimo Dimov, a professor at the University of Bathís School of Management, as having said that companies such as Pfizer (PFE), Merck (MRK), Roche (RHHBY) and AstraZeneca (AZN) are "closely watching" the firms. Cellectis (CLLS), which is working with Pfizer on its own approach to CAR-T therapy, has said it wants to bring its therapy to market and doesnít anticipate a sale, the report noted. Reference Link
06:50 EDTAZNAstraZeneca loses top executive Ward-Lilley to Vectura, Reuters reports
Subscribe for More Information
June 23, 2015
14:17 EDTPFEGlycoMimetics to receive $20M payment from Pfizer
Subscribe for More Information
14:01 EDTPFEPfizer announces enrollment of first patient in RESET study
Subscribe for More Information
09:53 EDTPFEPfizer management to meet with FBN Securities
Meeting to be held in New York on June 25 hosted by FBN Securities.
07:31 EDTAZNBIND Therapeutics announces FDA authorization of clinical trial with AZD2811
Subscribe for More Information
07:25 EDTPFEPiper Jaffray to hold a summit
2015 Piper Jaffray Heartland Summit is being held in Minneapolis on June 23-24.
June 22, 2015
08:52 EDTPFEPortola, Bristol-Myers, and Pfizer announce results from Phase 3 ANNEXA study
Subscribe for More Information
07:01 EDTPFEPfizer to acquire Nimenrix, Mencevax from GlaxoSmithKline for $130M
Pfizer (PFE) announced that it has entered into an agreement with GlaxoSmithKline (GSK) to acquire its quadrivalent meningitis ACWY vaccines, Nimenrix and Mencevax, for a total consideration of approximately $130M. This transaction will add two high-quality and complementary vaccines to Pfizerís portfolio, allowing the company to reach a broader global population. Nimenrix is a single dose meningococcal ACWY-TT conjugated vaccine designed to protect against Neisseria meningitidis, an uncommon but highly contagious disease that can lead to disability and death. Mencevax is a single-dose meningococcal ACWY unconjugated polysaccharide vaccine used to control outbreaks of meningococcal infection and for travelers to countries where the disease is endemic or highly epidemic. Pfizer does not expect this transaction to have any significant impact on its 2015 financial performance. The transaction is subject to customary closing conditions as well as regulatory approvals in several markets, and is expected to occur in the second half of 2015. Pfizerís legal advisors for the transaction were Ropes & Gray and Clifford Chance.
June 18, 2015
09:35 EDTPFEActive equity options trading on open
Subscribe for More Information
07:36 EDTAZNReceptos remains an attractive takeover candidate, says Leerink
Subscribe for More Information
June 17, 2015
10:00 EDTPFEOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: AbbVie (ABBV) initiated with an Overweight at Piper Jaffray... Arista Networks (ANET) initiated with a Buy at Sterne Agee CRT... Astec (ASTE) initiated with a Buy at Maxim... Bristol-Myers (BMY) initiated with an Underweight at Piper Jaffray... Community Healthcare (CHCT) initiated with an Outperform at Oppenheimer... Eli Lilly (LLY) initiated with an Overweight at Piper Jaffray... Fitbit (FIT) initiated with a Buy ahead of IPO at Dougherty... Hortonworks (HDP) initiated with a Buy at Mizuho... II-VI (IIVI) initiated with a Buy at Benchmark Co.... J Sainsbury (JSAIY) initiated with an Underperform at Credit Suisse... McDermott (MDR) initiated with an Outperform at Cowen... Merck (MRK) initiated with a Neutral at Piper Jaffray... Molina Healthcare (MOH) initiated with a Buy at UBS... Pacific DataVision (PDVW) initiated with a Buy at Canaccord... Pfizer (PFE) initiated with an Overweight at Piper Jaffray... Quest Resource (QRHC) initiated with a Buy at Roth Capital... Regional Management (RM) initiated with a Buy at Janney Capital... Rofin-Sinar (RSTI) initiated with a Buy at Benchmark Co.... Salesforce (CRM) initiated with a Neutral at Exane BNP Paribas... Sprouts Farmers Markets (SFM) initiated with a Neutral at Cleveland Research... Tesco (TSCDY) initiated with an Underperform at Credit Suisse... WM Morrison (MRWSY) initiated with a Neutral at Credit Suisse... WWE (WWE) initiated with a Buy at BTIG... World Acceptance (WRLD) initiated with a Buy at Janney Capital... Zafgen (ZFGN) initiated with a Buy at SunTrust.
07:25 EDTPFEPiper calls Bristol 'modestly overvalued,' starts shares with sell
Subscribe for More Information
05:31 EDTPFEPfizer initiated with an Overweight at Piper Jaffray
Target $45.
June 16, 2015
14:23 EDTAZNReceptos price target raised to $348 at Wedbush on M&A potential
Wedbush analysts Liana Moussatos and Kelechi Chikere said they'd interpreted Receptos (RCPT) comments with its earnings report in May about its ability to commercialize ozanimod on its own as a message to potential buyers that their bids were too low. Following a recent report from Proactive Investors, which claimed that Receptos had turned down bids of $200 per share from AstraZeneca (AZN) and $280 per share from Teva (TEVA) and Gilead (GILD), the analysts said they have reconsidered their valuation assumptions, as they believe these bid values could be accurate. Wedbush raised its fair value estimate on Receptos to $348 from $211, citing a belief in increased industry interest in ozanimod and the rest of Receptosí pipeline, and maintains an Outperform rating on the stock.
June 15, 2015
08:06 EDTAZNClovis price target raised to $115 from $85 at WallachBeth
WallachBeth analyst Bob Ai raised his raised for shares of Clovis Oncology (CLVS) to $115 from $85 and recommends using the recent pullback as a buying opportunity. Ai finds it inappropriate to directly compare the clinical data for Clovis's Rociletinib to AstraZeneca's (AZN) lung cancer drug AZD9291 due to differences in patients enrolled. He says not all news from ASCO 2015 is bad for Clovis and keeps a Buy rating on the name.
08:01 EDTPFEPfizer Consumer Healthcare to expand Caltrate, Centrum production in China
Pfizer Inc announced that it broke ground for a $95M consumer products production facility in Suzhou, China. The new site is near the companyís existing Suzhou site and will help increase production capacity to meet growing demand for Pfizer Consumer Healthcareís brands in China and the Asia-Pacific region. The new facility will primarily produce Caltrate dietary supplements and Centrum multivitamins, and in the future will support production of additional products. There are also plans to eventually house a research and development facility on the site to help support innovation in the region.
07:01 EDTPFEVentana receives FDA approval for IHC companion diagnostic for Xalkori
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use